US EditionMyosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Summary by Charleston Gazette-Mail
40 Articles
40 Articles
The Berkshire Eagle+39 Reposted by 39 other sources
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research…
Coverage Details
Total News Sources40
Leaning Left5Leaning Right3Center14Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 23%
C 64%
14%
Factuality
To view factuality data please Upgrade to Premium
